Mercado de tratamiento con terapia celular CAR-T en MEA: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de tratamiento con terapia con células CAR-T en MEA     

La creciente prevalencia del cáncer en la región de Oriente Medio y África es un factor clave para el mercado de tratamiento con terapia de células Car-T, lo que genera una creciente necesidad de tratamientos más efectivos. Sin embargo, el alto costo de la terapia con células Car-T presenta una barrera significativa, que potencialmente limita su accesibilidad. El lado positivo es que existe una oportunidad para el crecimiento del mercado a través del creciente enfoque de la región en el desarrollo de la infraestructura de atención médica y el turismo médico, particularmente en países como Singapur. Sin embargo, un desafío importante es la necesidad de realizar investigaciones y ensayos clínicos extensos para establecer la eficacia y seguridad a largo plazo de la terapia con células Car-T en esta región.    

Data Bridge Market Research analiza que se espera que el mercado de tratamiento de terapia con células CAR-T de MEA alcance los USD 105,69 millones para 2031, creciendo a una CAGR del 30,7% en el período de pronóstico de 2027 a 2031.    

Market Definition

CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein. These receptors are chimeric because they are combined with both antigen-binding and T-cell activating functions into a single receptor. Once the CAR-T cells infused in the patient’s body then they act as a “living cell” which has the ability or designed in such a way that they can kill the harmful cancer cells without affecting the healthy cells. The CAR-T cells when comes in contact with the targeted antigen on a cell, CAR-T cells binds with it and becomes activated and multiply to become cytotoxic.

MEA CAR-T Cell Therapy Treatment Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Increasing Prevalence of Cancer and other Target Diseases      

Cancer is a leading cause of morbidity and mortality worldwide, and the incidence of cancer is rising in these regions due to factors such as population growth, aging, and lifestyle changes. Additionally, there is a growing burden of other target diseases, such as hematological disorders, which can also be treated with CAR-T cell therapy. This increasing disease burden underscores the need for innovative and effective treatments like CAR-T cell therapy, driving market growth.

• Growing Awareness and Acceptance of Car-T Cell Therapy

The growing awareness and acceptance of CAR-T cell therapy as an effective treatment in the MEA, Saudi Arabia, and MEA regions are driven by various factors. These include heightened media coverage, educational efforts by healthcare organizations, and the sharing of success stories that highlight the therapy's effectiveness. Consequently, patients and healthcare providers are gaining a better understanding of CAR-T cell therapy's potential advantages, such as higher response rates and long-lasting remissions, especially in cases that are refractory or have relapsed. Additionally, regulatory approvals and endorsements in these regions have cemented CAR-T cell therapy's status as a legitimate and viable treatment option.

Opportunity

• The Extensive Pipeline of Car-T Cell Therapy

The extensive pipeline represents a wealth of opportunities for patients, healthcare providers, and the healthcare industry as a whole. This pipeline includes a range of CAR-T cell therapy products in various stages of development, from early preclinical Research to advanced clinical trials. The pipeline reflects ongoing innovation and investment in CAR-T cell therapy, with new products being developed to target different types of cancer and hematological disorders. Additionally, the pipeline includes products aimed at improving the safety, efficacy, and accessibility of CAR-T cell therapy, such as next-generation CAR-T cell therapies and off-the-shelf CAR-T cell products.

Restraints/Challenges

• High Cost of Car-T Cell Therapy

CAR-T cell therapy is a highly personalized and complex treatment that involves modifying a patient's immune cells to target cancer cells, making it a costly procedure. Factors contributing to this high cost include the specialized manufacturing process, extensive clinical monitoring, and infrastructure requirements. As a result, many patients, particularly those without adequate insurance coverage or financial resources, face challenges accessing this innovative therapy. The cost of clinical trials, regulatory compliance, and post-treatment monitoring further increases the overall expense, highlighting the financial burden for patients, especially those from lower-income backgrounds.

• Potential Risks and Adverse Effects of Treatment

CAR-T cell therapy, despite its promising efficacy, presents potential risks and side effects that pose challenges for patients and healthcare providers in the MEA, Saudi Arabia, and MEA regions. The most common side effects include cytokine release syndrome (CRS) and neurotoxicity. CRS, a significant adverse effect, occurs when infused CAR T cells recognize and attack cancer cells, leading to the release of cytokines like interleukin-6 (IL-6). This immune response causes systemic inflammation, manifesting in symptoms from mild fever and flu-like symptoms to potentially life-threatening complications like hypotension, respiratory distress, and multiorgan failure. CAR T-cell therapy can also trigger immune effector cell-associated neurotoxicity syndrome (ICANS), characterized by neurological symptoms such as confusion, seizures, and impaired speech. These side effects result from immune system overactivation and cytokine release, emphasizing the need for vigilant monitoring and prompt management to ensure patient safety and treatment efficacy.

Recent Developments

• In December 2023, Gilead Sciences, Inc. announced U.S. FDA has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy
• In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients by Japan's Ministry of Health, Labour and Welfare. This may help the company to strengthen its product portfolio
• In February 2022, the FDA has approved CARVYKTI™ (ciltacabtagene autoleucel) from Janssen for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, marking Janssen's inaugural cell therapy. This will underscore the dedication to advance their oncology treatment options
• In December 2021, Novartis AG has signed an agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), enhancing the company's immuno-oncology Research and development. This collaboration contributes to Novartis Oncology's broader initiative to advance innovation in cancer treatments by incorporating a potentially transformative therapy into its expanding immunotherapy platform

MEA CAR-T Cell Therapy Treatment Market Scope   

The MEA CAR-T cell therapy treatment market is segmented into seven notable segments based on product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Product

• Autologous CAR-T Cells
• Allogeneic CAR-T Cells

On the basis of product, the market is segmented into autologous CAR-T cells and allogeneic CAR-T cells.

Structure

• First Generation CAR-T Cells
• Second Generation CAR-T Cells
• Third Generation CAR-T Cells
• Fourth Generation CAR-T Cells 

On the basis of structure, the market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells, and fourth generation CAR-T cells.

Targeted Antigens

• Antigens on Solid Tumors
• Antigens on Hematologic Malignancies
• Others  

On the basis of targeted antigens, the market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. 

Brand

• Yescarta
• Kymriah
• Tecartus
• Others 

On the basis of brand, the market is segmented into yescarta, kymriah, tecartus and others.

Therapeutic Application

• Hematological Malignancies
• Pancreatic Cancer
• Breast Cancer
• Lung Cancer
• Gastric Cancer
• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse Large B-Cell Lymphoma
• Acute Lymphoblastic Leukemia (ALL)
• Others      

Sobre la base de la aplicación terapéutica, el mercado está segmentado en linfoma difuso de células B grandes, linfoma folicular, leucemia linfoblástica aguda (LLA), linfoma de células del manto, mieloma múltiple, neoplasias hematológicas, cáncer de pulmón, leucemia linfocítica crónica, cáncer gástrico, cáncer de páncreas, cáncer de mama y otros.   

Usuario final

• Hospitales
• Clínicas especializadas
• Otros

En función del usuario final, el mercado se segmenta en hospitales, clínicas especializadas y otros. 

Canal de distribución

• Farmacias Hospitalarias
• Otros

Sobre la base del canal de distribución, el mercado está segmentado en hospitales, farmacias y otros.

Análisis y perspectivas regionales del mercado de tratamiento con células CAR-T en MEA

El mercado de tratamiento con terapia con células CAR-T de MEA está segmentado en siete segmentos notables según el producto, la estructura, los antígenos objetivo, la marca, la aplicación terapéutica, el usuario final y el canal de distribución.

Los países cubiertos en este informe de mercado son Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Kuwait, Egipto y el resto de Medio Oriente y África.

Se espera que Arabia Saudita domine el mercado de tratamiento con terapia con células CAR-T en Oriente Medio y África debido a su avanzada infraestructura de atención médica, el apoyo gubernamental, el creciente sector de turismo médico, las actividades de investigación y desarrollo y la creciente demanda de tratamientos avanzados.

La sección de países del informe también proporciona factores individuales que impactan en el mercado y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas regionales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales y el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.

Análisis del panorama competitivo y de la cuota de mercado de los tratamientos con terapia celular CAR-T en la región MEA 

El panorama competitivo del mercado de tratamiento con células CAR-T de MEA proporciona detalles de los competidores. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las aprobaciones de productos, la amplitud y la extensión de los productos, el dominio de las aplicaciones y la curva de vida del tipo de producto. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa en el mercado.  

Algunos de los principales actores que operan en el mercado son Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company y Johnson & Johnson Services, Inc., entre otros.  

SKU-61531